Key result
Incident ICI-related myocarditis is linked to an ~8-fold higher risk of CV death.
Why the study?
It was unknown if Bonaca criteria for immune checkpoint inhibitor-related myocarditis correlate with cardiovascular adverse events, and whether incident myocarditis portends worse long-term cardiovascular outcomes.
Does immune checkpoint inhibitor-related myocarditis increase the risk of long-term cardiovascular comorbidities and cardiovascular death in oncology patients?
Comparison
Immune checkpoint inhibitor-related myocarditis vs random controls without concomitant immune-related adverse events
Design
Single-centre case-control study
Follow-up
2-year
Authors
Loading...
irM was associated with higher CV death risk; extends mixed prior data but leaves open need for prospective confirmation before changing surveillance.
Case-Control
No
Does immune checkpoint inhibitor-related myocarditis increase the risk of long-term cardiovascular comorbidities and cardiovascular death in oncology patients?
Effect estimate: HR 8.28
Absolute Event Rate: 93.4% vs 99.3%
p-value: p=0.048
Immune checkpoint inhibitor-related myocarditis is associated with significantly worse long-term cardiovascular outcomes, including an 8-fold increased risk of cardiovascular death.
Braghieri et al. (2024) conducted a case-control in Immune checkpoint inhibitor-related myocarditis. Immune checkpoint inhibitor-related myocarditis vs. Controls without other concomitant immune-related adverse events was evaluated on 2-year freedom from cardiovascular death (HR 8.28, p=0.048). Incident immune checkpoint inhibitor-related myocarditis was an independent predictor of cardiovascular death (HR 8.28, P=0.048) and associated with lower 2-year freedom from CV comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: